Abstract
Incidence of TNBC is much higher in developing countries like Pakistan. Although, new drugs like PARP inhibitors, Atezolizumab plus nab Paclitaxel, ipatisertib and Sacituzumab Govitecan are approved in metastatic TNBC, these are expensive and not readily available rendering chemotherapy remains main stay of treatment. BRCA mutations are often present in TNBC and Platinum drugs have shown their efficacy in BRCA mutated breast cancer. This study is aimed to look for response of platinum containing doublet in metastatic TNBC with unknown BRCA status as it’s cheaper and easily available.
Full Text
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call